EQS-Ad-hoc: DATAGROUP SE / Key word(s): Takeover DATAGROUP enters into an Investment Agreement with and supports a public purchase offer of KKR at a price of EUR 54.00 per share in cash 15-Apr-2025 / 23:54 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. DATAGROUP enters into an Investment Agreement with and supports a...
EQS-Ad-hoc: DATAGROUP SE / Schlagwort(e): Firmenübernahme DATAGROUP schließt eine Investorenvereinbarung mit und unterstützt öffentliches Erwerbsangebot von KKR zu einem Preis von EUR 54,00 in bar pro Aktie 15.04.2025 / 23:54 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pliezhausen, 15. April 2025....
EQS-Ad-hoc: Adtran Networks SE / Key word(s): Preliminary Results Adtran Networks SE updates preliminary results for the financial year 2024 15-Apr-2025 / 21:51 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Ad-hoc notification pursuant to Article 17 of the Market-Abuse-Regulation (EU) No. 596/2024 Adtran Networks SE:...
EQS-Ad-hoc: Adtran Networks SE / Schlagwort(e): Vorläufiges Ergebnis Adtran Networks SE passt die vorläufigen Ergebnisse für das Geschäftsjahr 2024 an 15.04.2025 / 21:51 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Ad-hoc-Mitteilung nach Artikel 17 der Marktmissbrauchs-verordnung (EU) Nr. 596/2014...
Fuller, Smith & Turner PLC (FSTA) Fuller, Smith & Turner PLC: Transaction in own shares 15-Apr-2025 / 17:53 GMT/BST Fuller, Smith & Turner P.L.C. (“the Company” or “Fuller’s”) Transaction in own shares The Company announces that it has purchased the following number of its ‘A' ordinary shares of 40p each on the London Stock Exchange through Numis Securities Limited as part of its share buyback programme announced on 14 March 2025 (the “Programme”). Date of Purchase 15/04/2025...
Gurit Holding AG / Key word(s): AGMEGM/Quarter Results GURIT REPORTS NET SALES OF CHF 85.2 MILLION IN THE FIRST QUARTER OF 2025; ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS 15-Apr-2025 / 18:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Zurich, April 15, 2025 – Ad hoc announcement pursuant to Art. 53 LR Gurit (SIX Swiss Exchange: GURN) today reports unaudited net sales results. Net sales reached...
ALTHEORA ALTHEORA: RESILIENCE DES RESULTATS ANNUELS 2024 15-Avr-2025 / 18:00 CET/CEST Information réglementaire transmise par EQS Group. Le contenu de ce communiqué est de la responsabilité de l’émetteur. Communiqué de presse Mauves, le 15 avril 2025 à 18h RESILIENCE DES RESULTATS ANNUELS 2024 Confirmation de la trajectoire d'amélioration des indicateurs financiers Cap vers CONFLUENCE 2030 : objectif 10% EBITDA En M€ 2024 2023 Chiffre d’affaires consolidé 37,0 41,3 EBITDA * 2,1 2,1...
Affluent Medical Affluent Medical progresse vers une étude clinique européenne sur le sphincter artificiel Artus pour le traitement de l'incontinence urinaire d'effort chez la femme. 15-Avr-2025 / 17:45 CET/CEST Information réglementaire transmise par EQS Group. Le contenu de ce communiqué est de la responsabilité de l’émetteur. ² Affluent Medical progresse vers une étude clinique européenne sur le sphincter artificiel Artus pour le traitement de l'incontinence urinaire d'effort chez...
Affluent Medical Affluent Medical Announces Progress Toward European Clinical Study of Artificial Sphincter Artus for the Treatment of Urinary Stress Incontinence in Women. 15-Apr-2025 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Affluent Medical Announces Progress Toward European Clinical Study of Artificial Sphincter Artus for the Treatment of Urinary Stress Incontinence in Women...
LIGHTON LIGHTON: FY 2024 results: transition to a SaaS model with recurring revenue. 15-Apr-2025 / 17:45 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Press release - Financial information Paris, April 15, 2025 FY 2024 results: transition to a SaaS model with recurring revenue First contract wins following the commercial launch of Paradigm in 2024; Robust financial structure to support...
LIGHTON LIGHTON: Résultats 2024 : transition vers un modèle SaaS à revenus récurrents. 15-Avr-2025 / 17:45 CET/CEST Information réglementaire transmise par EQS Group. Le contenu de ce communiqué est de la responsabilité de l’émetteur. Communiqué de presse - Information financière Paris, le 15 avril 2025 Résultats 2024 : transition vers un modèle SaaS à revenus récurrents Premiers succès commerciaux de Paradigm, lancé en 2024 Structure financière robuste pour soutenir un...
EQS-News: Affluent Medical SA / Key word(s): Study Affluent Medical Announces Progress Toward European Clinical Study of Artificial Sphincter Artus for the Treatment of Urinary Stress Incontinence in Women 15.04.2025 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Affluent Medical Announces Progress Toward European Clinical Study of Artificial Sphincter Artus for the Treatment of Urinary Stress Incontinence in Women SPHINX pilot study in women is set to...
EQS-News: Affluent Medical SA / Schlagwort(e): Studie Affluent Medical gibt Fortschritte im Hinblick auf die europäische klinische Studie mit dem künstlichen Harnröhrenschließmuskel Artus zur Behandlung der Belastungsinkontinenz bei Frauen bekannt 15.04.2025 / 17:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Affluent Medical gibt Fortschritte im Hinblick auf die europäische klinische Studie mit dem künstlichen Harnröhrenschließmuskel Artus zur...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Wood Group (John) plc 15-Apr-2025 / 15:27 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Spirent Communications plc 15-Apr-2025 / 15:26 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc 15-Apr-2025 / 15:26 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Assura plc 15-Apr-2025 / 15:25 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is...
The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Dalata Hotel Group plc 15-Apr-2025 / 15:24 GMT/BST Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Full name of discloser The Vanguard Group, Inc. Owner or controller of interests and short positions disclosed, if different from...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Greencore Group plc 15-Apr-2025 / 15:23 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Bakkavor Group plc 15-Apr-2025 / 15:23 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle...